Invalidity dossier
US 6165484
EDTA and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections
Current assignee: The University of Texas System
Added 9/23/2026, 2:24:53 PM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview: US 6165484 A
Title: EDTA and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections
Assignee/Current Assignee (per source): University of Texas System and Wake Forest University Health Sciences; original assignees Wake Forest University and University of Texas System. Inventors: Issam Raad, Robert Sheretz (spelled "Sherertz" in assignment records), and Ray Hachem.
Key dates: Priority date 1997-08-26; filing date 1998-08-25; granted/publication date 2000-12-26; anticipated expiration 2018-08-25. Legal status listed as "Expired – Fee Related."
Purpose: The invention relates generally to treating fungal infections in mammals, particularly systemic fungal infections, using pharmaceutical preparations including chelator(s), antifungal agents, and/or monoclonal antibodies. It addresses infections by Candida, Aspergillus, and Fusarium, noted as major causes of infection-related mortality in immunocompromised patients.
Plain-language scope: The patent describes a method of treating systemic fungal infection by administering a therapeutically effective amount of a composition comprising at least one chelator, at least one antifungal agent, and a pharmaceutical excipient, diluent, or adjuvant. A related method uses a chelator operatively attached to a monoclonal antibody plus an antifungal agent. "Chelator" is defined as a molecule having two or more nonmetal atoms capable of binding a metal ion in a heterocyclic ring; "antifungal agent" as a compound with fungicidal or fungistatic effect. Preferred chelators include EDTA and its salts and metal chelates, plus various aminopolycarboxylic acids. Antifungal agents listed include triazoles, cyclic lipopeptides, allylamines, imidazoles, polyenes (e.g., Amphotericin B, Nystatin), Griseofulvin, and Flucytosine.
Source: https://patents.google.com/patent/US6165484/en
What the excerpt does not establish: It does not provide full claim text, the complete specification, examples, dosage data, or experimental results. The excerpt is explicitly incomplete, so claim scope cannot be fully assessed. Nothing here establishes validity, enforceability, litigation history, or ownership transfers beyond the reassignments shown.
Generated 10/1/2026, 9:52:18 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 6165484. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.